Emma K. Beardsley

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer

Emma K. Beardsley, Sébastien J. Hotte, Scott North et al. · Investigational New Drugs · 2011 · 44 citations

Urology, Oncology, Genitourinary Cancer +7

Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer

Mitchell G. Lawrence, David Pook, Hong Wang et al. · The Prostate · 2015 · 40 citations

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer

Srikala S. Sridhar, Normand Blais, Ben Tran et al. · JAMA Oncology · 2020 · 36 citations · Full text

A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer

Arun Azad, Emma K. Beardsley, Sébastien J. Hotte et al. · Investigational New Drugs · 2014 · 30 citations

Urology, Medicine, Bicalutamide Versus +7

A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

K. N., Emma K. Beardsley, Peter Venner et al. · Journal of Clinical Oncology · 2008 · 21 citations

Effective Chemotherapy, Urology, Psa Response Rate +15